Sabin Goktas Aydin

Dr. Sabin Goktas Aydin

South Tees Hospitals NHS Foundation Trust, Middlesbrough, Redcar and Cleveland, UK
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2022 in Future Oncology
Verified
Journal Article
Open access
AYAyse Irem Yasin
Ayse Irem Yasin
SASabin Goktas Aydin
Sabin Goktas Aydin
BSBilge Sümbül
Bilge Sümbül
LKLokman Koral
Lokman Koral
MSMelih Simsek
Melih Simsek
MGMahmut Gümüş
Mahmut Gümüş
Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibod... Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccina...

14 April 2023 in Medicine
Verified
Journal Article
Open access
YKYasin Kutlu
Yasin Kutlu
SASabin Goktas Aydin
Sabin Goktas Aydin
ABAhmet Bilici
Ahmet Bilici
BObasak oven
basak oven
OOOmer Fatih Olmez
Omer Fatih Olmez
JHJamshid Hamdard
Jamshid Hamdard
Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy and evaluated the efficacy and safety of adding atezolizumab to chemotherapy for patients with ES-SCLC and prognostic and predictive factors as a real-life experience. This retrospective study included 55 patients who received front-line atezolizumab with etoposide plus platin regimen for ES-SCLC. We analyzed the survival outcomes and factors that may predict response and survival. The objective response rate (ORR) was 81.8%. At a median follow-up of 23.5 months, the median progression-free survival (PFS) time was 10.8 months, and the median overall survival (OS) time was 15.2 months. In univariate analysis for PFS, limited-stage disease at the time of diagnosis, the presence of prophylactic cranial irradiation (PCI), the presence of liver metastasis, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were found to be prognostic factors (P = .041, P = .034, P = .031, P = .004, and P = <.001, respectively). In other words, while the median PFS time was 14.1 months in patients with PLR ≤ 135.7, it was 7.5 months in patients with > 135.7. Similarly, median PFS was 14.9 months in patients with NLR ≤ 3.43, while it was 9.6 months in patients with > 3.43. Univariate analysis for OS revealed that limited stage at the time of diagnosis, NLR and PLR were significant prognostic indicators (P = .01, P = .006, and P = .007, respectively). Median OS time for patients with both NLR ≤ 3.43 and PLR ≤ 135.7 was significantly better than that of patients with NLR > 3.43 and PLR > 135.7 (16.9 vs 11.3 and 16.9 vs 11.5 months, respectively). Logistic regression analysis demonstrated that PLR was an independent significant predictive factor for the response to atezolizumab plus chemotherapy (OR: 0.07, P = .028). The patients with PLR ≤ 135.7 were significantly good responders to atezolizumab plus chemotherapy treatment. Real-life data demonstrated a significant correlation between survival and NLR and, PLR in ES-SCLC patients treated with atezolizumab. In addition, PLR was a significant predictive indicator of response to atezolizumab plus chemotherapy.

29 September 2023 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SASabin Goktas Aydin
Sabin Goktas Aydin
YKYasin Kutlu
Yasin Kutlu
HMHarun Muglu
Harun Muglu
AAAhmet Aydin
Ahmet Aydin
OAOzgur Acikgoz
Ozgur Acikgoz
OYOzcan Yildiz
Ozcan Yildiz

3 May 2022 in Breast Care
Verified
Journal Article
Open access
PDF file
SASabin Goktas Aydin
Sabin Goktas Aydin
ABAhmet Bilici
Ahmet Bilici
OOOmer Fatih Olmez
Omer Fatih Olmez
BOBasak B. Oven
Basak B. Oven
OAOzgur Acikgoz
Ozgur Acikgoz
JHJamshid Hamdard
Jamshid Hamdard
Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of NAC. Methods: A total of 186 LABC patients, treated with an NAC regimen according to tumor subtype, were retrospectively analyzed in this study. All patients underwent 18F-FDG PET/CT imaging before and after completion of NAC. PET parameters were measured in the most FDG avid breast tissue and axillary lymph nodes. We analyzed the correlation between the tumor SUVmax of the PET/CT response and the pCR after surgery. DFS was also evaluated with respect to pCR. Results: Higher pCR rates were significantly associated with a higher tumor grade, an initial Ki-67 ≥20% (p = 0.03 and p = 0.003, respectively), a triple-negative subtype (32.9%), and a human epidermal growth factor receptor 2 (HER-2)-positive subtype (24.7%) (p < 0.001). There was a significant correlation between the pCR and a complete response in 18F-FDG PET/CT (p < 0.001). The overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18F-FDG PET/CT to determine the pCR after NAC were 100%, 72.2%, 85%, 75.2%, and 100%, respectively. We demonstrated a 1.1 cutoff SUVmax for breast tumors after NAC (OR: 3.94, 95% CI: 1.14–5.05, p = 0.004), the 18F-FDG PET/CT response to NAC (OR: 0.50, 95% CI: 0.25–0.99, p = 0.003), and the molecular subtype of breast tumors (OR: 0.58, 95% CI: 0.38–0.88, p = 0.011). Conclusion: Our results confirm that 18F-FDG PET/CT is a useful method for predicting the NAC response in LABC.

22 September 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
SASabin Goktas Aydin
Sabin Goktas Aydin
ABAhmet Bilici
Ahmet Bilici
ECElif Calis
Elif Calis
YKYasin Kutlu
Yasin Kutlu
JHJamshid Hamdard
Jamshid Hamdard
OAOzgur Acikgoz
Ozgur Acikgoz

16 August 2022 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
SASabin Goktas Aydin
Sabin Goktas Aydin
BDBurcin Cakan Demirel
Burcin Cakan Demirel
ABAhmet Bilici
Ahmet Bilici
ATAtakan Topcu
Atakan Topcu
MAMusa Barış Aykan
Musa Barış Aykan
AAAhmet Aydin
Ahmet Aydin
Advanced stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study,...